Home Cart Sign in  
Chemical Structure| 188968-51-6 Chemical Structure| 188968-51-6

Structure of Cilengitide
CAS No.: 188968-51-6

Chemical Structure| 188968-51-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Cilengitide (EMD 121974) is a potent integrin antagonist with IC50s of 0.61 nM (ανβ3), 8.4 nM (ανβ5), and 14.9 nM (α5β1). It inhibits the binding of ανβ3 and ανβ5 to Vitronectin with IC50s of 4 nM and 79 nM, respectively. Cilengitide inhibits TGF-β/Smad signaling, mediates PD-L1 expression, induces apoptosis, and shows antiangiogenic effects in research against glioblastoma and other cancers.

Synonyms: EMD 121974; EMD-85189; EMD-12192

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Cilengitide

CAS No. :188968-51-6
Formula : C27H40N8O7
M.W : 588.66
SMILES Code : O=C(O)C[C@@H](C(N[C@H](CC1=CC=CC=C1)C(N(C)[C@@H](C(C)C)C(N[C@@H](CCCNC(N)=N)C(NC2)=O)=O)=O)=O)NC2=O
Synonyms :
EMD 121974; EMD-85189; EMD-12192
MDL No. :MFCD04307743
InChI Key :AMLYAMJWYAIXIA-VWNVYAMZSA-N
Pubchem ID :176873

Safety of Cilengitide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Cilengitide

cytoskeleton

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HMEC-1 1, 5, 50 μg/ml 24, 48, 72 hours Cilengitide caused dose-dependent detachment of endothelial cells from cell culture dishes, significantly inhibited endothelial cell proliferation, and increased the proportion of apoptotic cells. PMC2648308
G28 and G44 1, 5, 50 μg/ml 24, 48, 72 hours Cilengitide caused dose-dependent detachment of G28 and G44 glioma cells, inhibited cell proliferation, and induced apoptosis. PMC2648308
U87MG 1–100 μM 2 hours To evaluate the effect of Cilengitide on glioma cell attachment and viability, results showed that Cilengitide at clinically relevant concentrations induced detachment in some but not all glioma cell lines, while the effect on cell viability was modest. PMC2802395
LN-308 1–100 μM 2 hours To evaluate the effect of Cilengitide on glioma cell attachment and viability, results showed that Cilengitide at clinically relevant concentrations induced detachment in some but not all glioma cell lines, while the effect on cell viability was modest. PMC2802395
LN-18 1–100 μM 2 hours To evaluate the effect of Cilengitide on glioma cell attachment and viability, results showed that Cilengitide at clinically relevant concentrations induced detachment in some but not all glioma cell lines, while the effect on cell viability was modest. PMC2802395
T98G 1–100 μM 2 hours To evaluate the effect of Cilengitide on glioma cell attachment and viability, results showed that Cilengitide at clinically relevant concentrations induced detachment in some but not all glioma cell lines, while the effect on cell viability was modest. PMC2802395
LNT-229 1–100 μM 2 hours To evaluate the effect of Cilengitide on glioma cell attachment and viability, results showed that Cilengitide at clinically relevant concentrations induced detachment in some but not all glioma cell lines, while the effect on cell viability was modest. PMC2802395

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice PyMT-BO1-GFP-Luc MFP tumor model Intraperitoneal injection 20 mg/kg 10 consecutive days To evaluate the effect of Cilengitide on tumor growth, results showed that Cilengitide treatment significantly reduced tumor burden in β3KOM mice. PMC4944657
Mice Liver fibrosis model Intraperitoneal injection 1 mg/kg and 3 mg/kg Twice a week until the end of the experiment Cilengitide significantly reduced serum ALT and AST activities, inflammatory damage, and collagen deposition in the liver fibrosis model mice. PMC10808927
Mice Myocardial infarction model Intraperitoneal injection 5mg/kg Once daily for 5 days Inhibition of αvβ3 and αvβ5 integrins rescues cardiac function in Col5a1CKO animals PMC7415659

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01124240 Newly Diagnosed Non Methylated... More >> Glioblastoma Multiforme Grade 4 Less << PHASE2 UNKNOWN 2025-01-14 Royal North Shore Hospital, Sy... More >>dney, New South Wales, 2065, Australia Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.70mL

0.34mL

0.17mL

8.49mL

1.70mL

0.85mL

16.99mL

3.40mL

1.70mL

Dissolving Methods
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories